Baseline characteristics based on pre-HCT AI-ECG–predicted risk of AF
| . | Overall cohort . | Low AI-ECG–predicted AF . | High AI-ECG–predicted AF . | P value . |
|---|---|---|---|---|
| (N = 1377) . | (n = 1031) . | (n = 346) . | ||
| Transplant type | .13 | |||
| Allo | 529 (38%) | 408 (40%) | 121 (35%) | |
| Auto | 848 (62%) | 623 (60%) | 225 (65%) | |
| Patient age | 62 (55-68) | 61 (54-67) | 65 (60-70) | <.001 |
| Female | 578 (42%) | 483 (47%) | 95 (27%) | <.001 |
| Diabetes mellitus | 153 (11%) | 99 (9.6%) | 54 (16%) | .002 |
| Vascular disease | 153 (11%) | 82 (8.0%) | 71 (21%) | <.001 |
| AF | 88 (6.4%) | 32 (3.1%) | 56 (16%) | <.001 |
| Disease histology | <.001 | |||
| Acute leukemia | 363 (26%) | 281 (27%) | 82 (24%) | |
| Plasma cell disease | 848 (62%) | 623 (60%) | 225 (65%) | |
| MDS | 166 (12%) | 127 (12%) | 39 (11%) | |
| High-risk (3+) HCT-CI | 703 (51%) | 493 (48%) | 210 (61%) | <.001 |
| Remission status at HCT | 1200 (87%) | 903 (88%) | 297 (86%) | .4 |
| . | Overall cohort . | Low AI-ECG–predicted AF . | High AI-ECG–predicted AF . | P value . |
|---|---|---|---|---|
| (N = 1377) . | (n = 1031) . | (n = 346) . | ||
| Transplant type | .13 | |||
| Allo | 529 (38%) | 408 (40%) | 121 (35%) | |
| Auto | 848 (62%) | 623 (60%) | 225 (65%) | |
| Patient age | 62 (55-68) | 61 (54-67) | 65 (60-70) | <.001 |
| Female | 578 (42%) | 483 (47%) | 95 (27%) | <.001 |
| Diabetes mellitus | 153 (11%) | 99 (9.6%) | 54 (16%) | .002 |
| Vascular disease | 153 (11%) | 82 (8.0%) | 71 (21%) | <.001 |
| AF | 88 (6.4%) | 32 (3.1%) | 56 (16%) | <.001 |
| Disease histology | <.001 | |||
| Acute leukemia | 363 (26%) | 281 (27%) | 82 (24%) | |
| Plasma cell disease | 848 (62%) | 623 (60%) | 225 (65%) | |
| MDS | 166 (12%) | 127 (12%) | 39 (11%) | |
| High-risk (3+) HCT-CI | 703 (51%) | 493 (48%) | 210 (61%) | <.001 |
| Remission status at HCT | 1200 (87%) | 903 (88%) | 297 (86%) | .4 |
MDS, myelodysplastic syndrome.